The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2016 | Panobinostat and donor lymphocyte infusions in patients with high-risk AML and MDS
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Gesine Bug, MD from University Hospital Frankfurt, Frankfurt/Main, Germany discusses a clinical trial with 40 high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients treated with panobinostat and donor lymphocyte infusions (DLI). Promising results of the study showing that the combination of the two treatments has a potential to inhibit a disease relapse will be validated further in a randomised clinical trial next year.
